Solesta, an injectable gel delivered into the anal canal in an outpatient procedure, is a minimally invasive treatment option.
The FDA previously noted difficulties in treating fecal incontinence.
Related Articles on Incontinence:
FDA Approves Solesta to Treat Life-Altering Fecal Incontinence
FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product
USC Colorectal Surgeon Andreas Kaiser Named GI Journal Editor
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
